Skip to main content


Thresholds of various glycemic measures for diagnosing diabetes based on prevalence of retinopathy in community-dwelling Japanese subjects: the Hisayama Study



There has been controversy over the diagnostic thresholds of hemoglobin A1c (HbA1c) for diabetes. In addition, no study has examined the thresholds of glycated albumin (GA) and 1,5-anhydroglucitol (1,5-AG) for diagnosing diabetes using the presence of diabetic retinopathy (DR). We examined the optimal thresholds of various glycemic measures for diagnosing diabetes based on the prevalence of DR in community-dwelling Japanese subjects.


A total of 2,681 subjects aged 40-79 years underwent a 75-g oral glucose tolerance test, measurement of HbA1c, GA, and 1,5-AG, and an ophthalmic examination in 2007-2008. The associations of glycemic measures with DR status were examined cross-sectionally. DR was assessed by an examination of the fundus photograph of each eye and graded according to the International Clinical Diabetic Retinopathy Disease Severity Scale. We divided the values of glycemic measures into ten groups on the basis of deciles. The receiver operating characteristic (ROC) curve analysis was performed to determine the optimal threshold of each glycemic measure for detecting the presence of DR.


Of the subjects, 52 had DR. The prevalence of DR increased steeply above the ninth decile for fasting plasma glucose (FPG) (6.2-6.8 mmol/l), for 2-hour postload glucose (PG) (9.2-12.4 mmol/l), for HbA1c (5.9-6.2% [41-44 mmol/mol]), and for GA (16.2-17.5%), and below the second decile for 1,5-AG (9.6-13.5 μg/mL). The ROC curve analysis showed that the optimal thresholds for DR were 6.5 mmol/l for FPG, 11.5 mmol/l for 2-hour PG, 6.1% (43 mmol/mol) for HbA1c, 17.0% for GA, and 12.1 μg/mL for 1,5-AG. The area under the ROC curve (AUC) for 2-hour PG (0.947) was significantly larger than that for FPG (0.908), GA (0.906), and 1,5-AG (0.881), and was marginally significantly higher than that for HbA1c (0.919). The AUCs for FPG, HbA1c, GA, and 1,5-AG were not significantly different.


Our findings suggest that the FPG and HbA1c thresholds for diagnosing diabetes in the Japanese population are lower than the current diagnostic criterion, while the 2-hour PG threshold is comparable with the diagnostic criterion. 2-hour PG had the highest discriminative ability, whereas FPG, HbA1c, GA, and 1,5-AG were similar in their ability.


The International Expert Committee [1, 2], the American Diabetes Association [3], and the World Health Organization [4] recently proposed the use of hemoglobin A1c (HbA1c) to diagnose diabetes at a threshold of 6.5% (48 mmol/mol). This threshold was based primarily on the findings of several epidemiological studies in Western populations that investigated HbA1c levels associated with a higher prevalence of diabetic retinopathy (DR), the most specific microvascular complication of diabetes [57]. It has been reported that a higher HbA1c level was significantly associated with DR in subjects with diabetes [8], and some clinical trials have demonstrated that lowering HbA1c levels decreased the risk of microvascular complications, such as DR, in diabetes patients [911]. These findings suggest that HbA1c levels are intimately related to the risk of DR, and this evidence supports the use of HbA1c as a diagnostic tool for diabetes. However, there has been controversy over the diagnostic threshold of HbA1c. An integrated study of three general populations has shown that the relation between fasting plasma glucose (FPG) levels and the prevalence of retinopathy was continuous, with no clear threshold [12], whereas a prospective study of a French population recently revealed that the optimal threshold of HbA1c for incident retinopathy was 6.0%, which is below the current diagnostic criterion [13]. In addition, several cross-sectional studies of Asian populations, including our previous study, have examined this issue [1418], but the optimal HbA1c thresholds have differed among these investigations. Thus, a reevaluation of threshold of HbA1c for DR is needed.

Glycated albumin (GA) and 1,5-anhydroglucitol (1,5-AG) levels, which are serum markers of hyperglycemia, have also been found to be significantly associated with microvascular complications [19, 20]. There have been a few studies investigating GA [2123] and 1,5-AG levels [2426] to detect subjects with glucose intolerance defined by glucose levels, but no study has examined the diagnostic thresholds of these glycemic measures for diabetes based on the presence of DR, and it is uncertain whether GA and 1,5-AG measurements are applicable as a diagnostic tool for diabetes [27, 28]. In addition, in the general Asian community, there are limited data assessing FPG and 2-hour postload glucose (PG) levels associated with the prevalence of DR [14, 17, 29].

The purposes of this study were to determine the thresholds of FPG, 2-hour PG, HbA1c, GA, and 1,5-AG for the diagnosis of diabetes based on the prevalence of DR in a community-dwelling Japanese population, and to compare the ability of these five glycemic measures to differentiate subjects with and without DR.


Study population

A population-based prospective study of cardiovascular disease and its risk factors has been underway since 1961 in the town of Hisayama, a suburb of the Fukuoka metropolitan area on Japan’s Kyushu Island. The population of the town has been stable for 50 years and was approximately 8,400 in 2010. The age and occupational distributions, and nutritional intake of the population were similar to those of Japan as a whole based on data from the national census and nutrition survey [30, 31]. In 2007 and 2008, a cross-sectional survey for the present study was performed in the town. A detailed description of this survey was published previously [30]. There were a total of 3,835 residents aged 40-79 years based on the town registry, and 2,957 (participation rate, 77.1%) took part in a comprehensive assessment, including a 75-g oral glucose tolerance test (OGTT), the measurement of HbA1c, and an ophthalmic examination. We excluded the eight subjects who did not consent to participate in the study, 46 who had already had breakfast, 35 who were on insulin therapy, and 156 who refused the OGTT, leaving a total of 2,712 subjects who completed both the 75-g OGTT and HbA1c measurement. Among these, 21 subjects who lacked ophthalmic examination information and 10 for whom there was no measurement of GA or 1,5-AG were excluded, and the remaining 2,681 subjects (1,192 men, 1,489 women) were enrolled in the present study.

Clinical evaluation and laboratory measurements

The study subjects underwent the OGTT between 8:00 and 10:30 A.M. after an overnight fast of at least 12 hours. Blood for the glucose assay was obtained by venipuncture into tubes containing sodium fluoride at fasting and at 2-hour postload, and was separated into plasma and blood cells within 20 min. Plasma glucose concentrations were determined by the hexokinase method. According to the 1998 World Health Organization criteria [32], diabetes was defined as FPG ≥7.0 mmol/l or 2-hour PG ≥11.1 mmol/l or both, or the use of antidiabetic medications. Those who were diagnosed with diabetes with or without treatment before the examination were considered to be cases of known diabetes. Blood samples were also collected for the determination of HbA1c levels, hemoglobin (Hb) and serum creatinine concentrations. HbA1c levels were measured by latex aggregation immunoassay (Determiner HbA1C; Kyowa Medex, Tokyo, Japan). The values for HbA1c were estimated as a National Glycohemoglobin Standardization Program (NGSP) equivalent value calculated with the formula: HbA1c (%) = 1.02 × HbA1c (Japan Diabetes Society [JDS]) (%) + 0.25% [33]. A portion of each serum specimen was stored at -80°C for 5 years until it was used for measurement of GA and 1,5-AG in 2012. Serum GA levels were determined by an enzymatic method using an albumin-specific proteinase, ketoamine oxidase, and an albumin assay reagent (Lucica GA-L; Asahi Kasei Pharma, Tokyo, Japan). Serum 1,5-AG concentrations were measured enzymatically (Lana 1,5AG Auto Liquid; Nippon Kayaku, Tokyo, Japan). Hb concentrations were measured by sodium lauryl sulfate-hemoglobin method. Anemia was defined as Hb <13.0 g/dL for men and <12.0 g/dL for women [34]. Serum creatinine concentrations were measured enzymatically, and estimated glomerular filtration rate (eGFR) was calculated using the following new Japanese equation: eGFR (mL/min/1.73 m2) = 194 × (serum creatinine [mg/dL])−1.094 × (age [years])−0.287 × (0.739 if female) [35]. Renal failure was defined as an eGFR <30 mL/min/1.73 m2 (chronic kidney disease stage 4 or 5) [36].

The height and weight were measured with the subject in light clothes without shoes, and the body mass index (BMI) (kg/m2) was calculated. Each participant completed a self-administered questionnaire covering medical history and antidiabetic treatment.

Ophthalmic examination and definition of diabetic retinopathy

The methods used for the ophthalmic examination have been described in detail previously [14]. Briefly, each participant underwent fundus photographs for the assessment of DR. After pupil dilatation with 1.0% tropicamide and 10% phenylephrine, fundus photographs (45°) were taken from both eyes of each participant using a Topcon digital TRC NW-6SF fundus camera (Topcon Corporation, Tokyo, Japan). The photographs were taken in 1-field per eye, centered on the macula. The photographs were assessed by photographic graders who were masked to the clinical information. The severity of DR was classified into 5 categories according to the International Clinical Diabetic Retinopathy Disease Severity Scale: no retinopathy (equivalent to the Early Treatment of Diabetic Retinopathy Study [ETDRS] scale level 10), mild nonproliferative DR (equivalent to ETDRS level 20), moderate nonproliferative DR (equivalent to ETDRS levels 35, 43, and 47), severe nonproliferative DR (equivalent to ETDRS levels 53A-53E), and proliferative DR (equivalent to ETDRS levels 61 or higher) [37]. The degree of DR was determined according to the grading in the worse eye. The presence of DR was defined as the presence of mild or moderate or severe nonproliferative DR, or proliferative DR in either eye.

Statistical analysis

The SAS software package version 9.3 (SAS Institute, Cary, NC) was used to perform all statistical analyses. We assessed the statistical significance of differences in the prevalence or mean of each factor among the DR status groups by using a logistic or linear regression model, respectively. To analyze FPG, 2-hour PG, HbA1c, GA, and 1,5-AG levels as categorical variables, these values were divided into ten groups on the basis of deciles. The receiver operating characteristic (ROC) curve analysis was performed to determine the optimal threshold of each glycemic measure for detecting the presence of DR. The optimal threshold was obtained from the point on the ROC curve closest to the ideal of 100% sensitivity and 100% specificity. The discrimination of each measure of glycemia for DR was assessed by the area under the ROC curve (AUC). The difference in the AUC was estimated using the method of DeLong et al. [38]. A value of p < 0.05 was considered statistically significant in all analyses.

Ethical considerations

This study was conducted with the approval of the Kyushu University Institutional Review Board for Clinical Research, and written informed consent was obtained from all the participants.


Of the study participants, 52 (1.9%) had DR. Mild nonproliferative DR, moderate nonproliferative DR, severe nonproliferative DR, and proliferative DR were found in 33 (1.2%), 6 (0.2%), 13 (0.5%), and 0 (0%) subjects, respectively. The clinical characteristics of subjects are shown in Table 1. The mean age of participants was 60 years, and men comprised 44.5% of the group. The prevalence of diabetes, known diabetes, anemia, and renal failure was 15.2%, 10.0%, 13.2%, and 0.3%, respectively. The mean values of age, FPG, 2-hour PG, HbA1c, GA, diabetes duration and BMI, and the frequencies of men, diabetes, and known diabetes were significantly higher in the subjects with DR than in those without DR, and the subjects with DR had significantly lower 1,5-AG values. The mean values of Hb and eGFR and the frequencies of anemia and renal failure did not differ between the groups.

Table 1 Clinical characteristics of subjects, 2007-2008

Figure 1A shows the prevalence of DR by deciles of the distribution of FPG, 2-hour PG, HbA1c, and GA levels. The prevalence of DR was very low in the first through eighth deciles for each glycemic measure, but started to increase steeply from the ninth decile for FPG (6.2-6.8 mmol/l), 2-hour PG (9.2-12.4 mmol/l), HbA1c (5.9-6.2% [41-44 mmol/mol]), and GA (16.2-17.5%). Figure 1B demonstrates the prevalence of DR by deciles of 1,5-AG levels. The prevalence of DR increased markedly below the second decile for 1,5-AG (9.6-13.5 μg/mL), while there was no apparent increase in the prevalence of DR between the third and the tenth deciles of 1,5-AG.

Figure 1

Prevalence of diabetic retinopathy by deciles of the distribution of fasting plasma glucose, 2-hour postload glucose, hemoglobin A 1c , glycated albumin (A), and 1,5-anhydroglucitol levels (B). FPG: fasting plasma glucose; 2-hour PG: 2-hour postload glucose; HbA1c: hemoglobin A1c; GA: glycated albumin; 1,5-AG: 1,5-anhydroglucitol.

The optimal thresholds of each glycemic measure for detecting prevalent DR using ROC curve analyses are shown in Table 2. The optimal threshold was 6.5 mmol/l for FPG, 11.5 mmol/l for 2-hour PG, 6.1% (43 mmol/mol) for HbA1c, 17.0% for GA, and 12.1 μg/mL for 1,5-AG. The sensitivity, specificity, positive predictive value, and negative predictive value of these thresholds were 82.7%, 86.6%, 10.9%, and 99.6% for FPG, 90.4%, 89.3%, 14.3%, and 99.8% for 2-hour PG, 86.5%, 88.8%, 13.3%, and 99.7% for HbA1c, 86.5%, 89.0%, 13.5%, and 99.7% for GA, and 78.8%, 85.8%, 9.9%, and 99.5% for 1,5-AG, respectively. Among the five glycemic measures, 2-hour PG threshold of 11.5 mmol/l had the highest sensitivity, while 1,5-AG threshold of 12.1 μg/mL showed the lowest sensitivity. In addition, with the exception of the thresholds for 2-hour PG and 1,5-AG, the thresholds of the glycemic measures were not substantially changed when DR was defined as a moderate or higher level of retinopathy (6.5 mmol/l for FPG, 13.1 mmol/l for 2-hour PG, 6.3% [45 mmol/mol] for HbA1c, 17.2% for GA, and 10.8 μg/mL for 1,5-AG).

Table 2 Thresholds of FPG, 2-hour PG, HbA 1c , GA, and 1,5-AG levels for detecting diabetic retinopathy

To evaluate the ability of each glycemic measure to identify the presence of DR, we compared the AUC among glycemic measures (Figure 2). The AUC for 2-hour PG was 0.947 (95% confidence interval [CI] 0.922-0.971), which was significantly larger than that for FPG (0.908 [95% CI 0.866-0.949]; p = 0.01), GA (0.906 [95% CI 0.853-0.960]; p = 0.03), and 1,5-AG (0.881 [95% CI 0.824-0.937]; p = 0.01), and was marginally significantly higher than that for HbA1c (0.919 [95% CI 0.878-0.959]; p = 0.07). The AUC for 1,5-AG was lower than that for other measures of glycemia, but there was no significant difference in the AUC among FPG, HbA1c, GA, and 1,5-AG.

Figure 2

Comparison of the discriminative ability of fasting plasma glucose, 2-hour postload glucose, hemoglobin A 1c , glycated albumin, and 1,5-anhydroglucitol for detecting the presence of diabetic retinopathy. FPG: fasting plasma glucose; 2-hour PG: 2-hour postload glucose; HbA1c: hemoglobin A1c; GA: glycated albumin; 1,5-AG: 1,5-anhydroglucitol; CI: confidence interval.


Using data from a cross-sectional survey in a Japanese community, we demonstrated that the optimal thresholds for detecting prevalent DR from ROC analyses were 6.5 mmol/l for FPG, 11.5 mmol/l for 2-hour PG, 6.1% (43 mmol/mol) for HbA1c, 17.0% for GA, and 12.1 μg/mL for 1,5-AG. These results were in accordance with those from the prevalence analysis of DR by decile levels of these measures of glycemia. These findings suggest that the FPG and HbA1c thresholds for diagnosing diabetes in the Japanese population are lower than the current diagnostic criterion, while the 2-hour PG threshold is approximately 11.1 mmol/l, which is comparable to the diagnostic criterion. To our knowledge, the present study is the first report to determine the GA and 1,5-AG thresholds for the diagnosis of diabetes using the prevalence of DR. Furthermore, 2-hour PG had higher sensitivity and larger AUC than other glycemic measures, whereas the AUCs for FPG, HbA1c, GA, and 1,5-AG were not significantly different. These findings indicate that 2-hour PG has the highest discriminative ability, and measurements of FPG, HbA1c, GA, and 1,5-AG are similar in their ability.

The HbA1c thresholds for identifying presence of DR have varied among prior epidemiological studies of Asian populations, ranging from 6.1% (43 mmol/mol) to 7.0% (53 mmol/mol). In a study in a Singapore population, the optimal HbA1c threshold for DR was 6.6-7.0% (49-53 mmol/mol) [15]. A subanalysis of the DETECT-2, which included three Asian studies in India, Singapore, and Japan, showed that an HbA1c of 6.4% (46 mmol/mol) was the optimal threshold [16]. Similar findings were observed in a Chinese population study (6.4% [46 mmol/mol]) [17]. On the other hand, in the present study, the prevalence of DR increased precipitously when HbA1c levels exceeded 5.9-6.2% (41-44 mmol/mol), and the optimal threshold of HbA1c using the ROC analysis was 6.1% (43 mmol/mol). Importantly, this threshold was identical with that from our previous study in 1998 (NGSP: 6.1% [43 mmol/mol]; JDS: 5.7%) [14]. Furthermore, in another epidemiological study in a Japanese population, the ROC analysis indicated that the highest precision for DR was observed at an HbA1c value of 6.2% (44 mmol/mol) [18]. These findings suggest that the HbA1c threshold in the Japanese population was lower than that of other Asians and also lower than the diagnostic criterion of 6.5% (48 mmol/mol). Although the reason for this difference is unclear, the influence of race and ethnicity on HbA1c levels may contribute to this phenomenon. Some epidemiological studies have shown that South Asians, Hispanics, and Blacks had higher HbA1c levels than non-Hispanic whites, independent of glucose [39, 40]. In our subjects, the mean of HbA1c levels (5.5% [37 mmol/mol]) was lower than those in other Asian population studies (6.0-6.5% [42-48 mmol/mol]) [1517]. Thus, it is speculated that there are racial and ethnic differences in HbA1c levels even among Asians, and this may be the reason for the lower threshold in our subjects. In addition, the aldehyde dehydrogenase 2*2 (ALDH2*2) allele, which is more common in East Asians than in other ethnic groups, has been identified as a genetic risk factor for incident DR in Japanese subjects with diabetes [41], and thus, such a genetic difference in susceptibility to DR might also affect the HbA1c levels associated with incident DR.

The use of HbA1c measurement to diagnose diabetes remains somewhat controversial [42]. Recent epidemiological studies have revealed that HbA1c measurement alone was less sensitive for detecting subjects with diabetes compared to the OGTT [43, 44]. However, in our study, the AUCs for HbA1c and FPG were not significantly different. This finding indicates that the discriminative ability of HbA1c for diagnosing diabetes was comparable to that of FPG. Furthermore, HbA1c measurement can be done without fasting or timed samples, and thus it would be suitable for mass screening in general practice. This advantage has implications for the early identification and treatment of undiagnosed diabetes. For these reasons, HbA1c measurement may be an appropriate tool for detecting undiagnosed diabetes. In addition, some clinical and population-based studies, including our previous study, have shown that elevated HbA1c levels were independently associated with cardiovascular disease [45, 46], suggesting that HbA1c is also useful as a predictor of macrovascular complications. Therefore, the use of HbA1c to diagnose diabetes will help to prevent both micro- and macrovascular complications of diabetes, which are increasingly recognized as a global health priority.

In the present analysis, although the prevalence of DR was quite small for GA below 16.2-17.5%, it began to rise sharply above these levels, and the optimal threshold of GA using the ROC analysis was 17.0%. Several studies have examined the use of GA levels for detecting diabetes or glucose intolerance, as defined by glucose levels. In a Japanese population study, the ROC analysis for detecting diabetes identified the GA threshold as 15.5% [23], while another study of Japanese subjects reported a GA level of 17.0% as the lower limit of glucose intolerance [21]. A similar threshold of GA was obtained in a Chinese population study (17.1%) [22]. The thresholds in these studies were in good agreement with our findings. Together with those of other studies, our findings suggest that the optimal GA threshold for diagnosing diabetes is likely to be 17.0%.

There have been a few studies evaluating the optimal threshold of 1,5-AG for identifying individuals with diabetes, as defined by a OGTT. A Japanese population study showed that 14.0 μg/mL was the best value for detecting subjects with diabetes [24]. Similar findings were observed among Japanese male workers (14.2 μg/mL) [26]. In a Chinese study, the mean of 1,5-AG levels was 15.0 μg/mL in subjects with newly diagnosed diabetes and 11.8 μg/mL in subjects with known diabetes [25]. However, no study showed an optimal threshold of 1,5-AG using the presence of DR. The present study revealed that the steepest increment in the prevalence of DR occurred when the 1,5-AG levels fell below 9.6-13.5 μg/mL, and that 12.1 μg/mL was the optimal 1,5-AG threshold in the ROC analysis. Further epidemiological studies are needed to verify our findings.

The FPG of 7.0 mmol/l and the 2-hour PG of 11.1 mmol/l for diagnosing diabetes with the current criterion were also derived mainly from studies in Western populations [7]. In our study, the optimal threshold for detecting prevalent DR was 6.5 mmol/l for FPG, and 11.5 mmol/l for 2-hour PG. The 2-hour PG threshold was compatible with that from our previous report (11.1 mmol/l) [14] and another study of a Japanese population (11.0 mmol/l) [29]. Meanwhile, other Asian population studies have reported that the optimal FPG threshold for DR was 7.0 mmol/l in a Japanese population [29], and 7.2 mmol/l in a Chinese population [17]. These findings are inconsistent with ours. However, a recent meta-analysis in Asian and Western populations evaluated the relationship of glucose levels with DR and concluded that the FPG threshold for diagnosing diabetes was 6.5 mmol/l [16]. Furthermore, our prior studies showed that the threshold of FPG for DR was 6.4 mmol/l [14] and that the FPG threshold corresponding to a 2-h PG of 11.1 mmol/l was 6.2 mmol/l [47]. These results were very similar to those of the present study. Taken together, these findings imply that, in a Japanese population, the threshold of FPG for diabetes is lower than the diagnostic criterion of 7.0 mmol/l, while the threshold of 2-hour PG is 11.1 mmol/l, which is in accord with the diagnostic criterion.

The present study showed that among the five glycemic measures, 2-hour PG had not only the highest sensitivity but also the largest AUC to identify the presence of DR. These results suggest that the performance and discriminative ability of 2-hour PG for diagnosing diabetes were superior to those of other glycemic measures. Oxidative stress is known to be one of the crucial contributors in the pathogenesis of DR [48]. It has also been reported that acute hyperglycemia had a more specific triggering effect on oxidative stress than chronic sustained hyperglycemia [49, 50]. Thus, 2-hour PG values can be considered a better marker of oxidative stress levels arising from acute hyperglycemia than FPG, HbA1c, GA, and 1,5-AG values. Furthermore, a prospective study demonstrated that postprandial plasma glucose was a stronger predictor of the progression of DR than HbA1c in Japanese subjects with diabetes [51]. Taken together, these findings imply that 2-hour PG levels may be more strongly associated with DR than other glycemic measures. This may explain why 2-hour PG has a high diagnostic accuracy for DR. On the other hand, the AUCs for GA and 1,5-AG did not significantly differ from those for FPG and HbA1c, suggesting that GA and 1,5-AG are acceptable alternatives for the diagnosis of diabetes, and these two measures may be particularly useful for individuals with anemia, renal disease or hemoglobinopathy, for whom interpretation of HbA1c values is problematic. However, the 1,5-AG levels had smaller AUC with lower sensitivity than other glycemic measures. One possible explanation for this phenomenon may be that 1,5-AG levels reflect the degree of glycosuria rather than glucose levels [28], while other glycemic measures directly indicate the degree of hyperglycemia. In addition, it has been reported that 1,5-AG levels were influenced by individual difference in their renal thresholds for glucose [52]. These facts might be the reason for the relatively low discriminative ability of 1,5-AG in our study.

The strengths of our study include the population-based design, high participation rate, and availability of data to evaluate the five glycemic measures. In addition, it is noteworthy that the FPG, 2-hour PG, and HbA1c thresholds in the present study were nearly the same as those from our previous study [14], suggesting the high reproducibility of the results in our population. However, some limitations should also be mentioned. First, our analyses included subjects with antidiabetic medications. Hypoglycemic medications could have affected the levels of glycemia. The optimal thresholds remained substantially unchanged, except for GA, after excluding subjects who received hypoglycemic medications (FPG: 6.3 mmol/l; 2-hour PG: 11.5 mmol/l; HbA1c: 6.2% [44 mmol/mol]; GA: 20.5%; and 1,5-AG: 12.1 μg/mL). However, the precision of this finding may be limited, because of the small number of cases of DR among those not taking hypoglycemic medications. Second, the values of HbA1c were not measured by high-performance liquid chromatography (HPLC) as used in the Diabetes Control and Complications Trial, although the method and reagent used to measure HbA1c in this study have since been NGSP-certified. It would be preferable to measure HbA1c by HPLC to make the results of our study more comparable to those of other studies. Third, the GA and 1,5-AG levels were measured in serum conserved at -80°C for 5 years. However, the stability of GA and 1,5-AG measurements in frozen stored serum sample was preserved [53, 54]. Fourth, this study is a cross-sectional design, which might have affected the threshold values of glycemic measures. Diagnostic thresholds would ideally be derived from prospective studies that examine the relationship between measures of glycemia and incident microvascular complications. Lastly, the influence of factors that may affect HbA1c levels, such as anemia, renal failure, and hemoglobinopathy should be considered. We performed sensitivity analyses excluding subjects with anemia or renal failure, and the optimal threshold of HbA1c remained unchanged (6.1% [43 mmol/mol]). Furthermore, the prevalence of hemoglobinopathy in Japan was reported to be very low (0.04%) [55]. Therefore, the influence of this limitation would have been small.


The present analysis showed that, in a Japanese population, the FPG and HbA1c threshold for diagnosing diabetes was lower than the current diagnostic criterion, while the 2-hour PG threshold was consistent with the diagnostic criterion, and the discriminative ability of 2-hour PG was superior to other glycemic measures. These findings suggest that the threshold of 2-hour PG is 11.1 mmol/l, regardless of race, whereas ethnic-specific thresholds of FPG and HbA1c may be necessary. This study also demonstrated the potential applicability of GA and 1,5-AG measurements as a diagnostic tool for diabetes. Further prospective studies are needed to verify these findings, and investigations of HbA1c levels in the intermediate range are also required.



Hemoglobin A1c


Diabetic retinopathy


Fasting plasma glucose


Glycated albumin


5-AG: 1,5-anhydroglucitol


Postload glucose


Oral glucose tolerance test




National Glycohemoglobin Standardization Program


Japan Diabetes Society


Estimated glomerular filtration rate


Body mass index


Early Treatment of Diabetic Retinopathy Study


Receiver operating characteristic


Area under the receiver operating characteristic curve


Confidence interval


High-performance liquid chromatography.


  1. 1.

    International Expert Committee: International expert committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009, 32: 1327-1334.

  2. 2.

    Gillett MJ: International expert committee report on the role of the A1C assay in the diagnosis of diabetes: Diabetes Care 2009; 32(7): 1327-1334. Clin Biochem Rev. 2009, 30: 197-200.

  3. 3.

    American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010, 33 (Suppl 1): S62-S69.

  4. 4.

    World Health Organization: Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus. 2011

  5. 5.

    McCance DR, Hanson RL, Charles MA, Jacobsson LT, Pettitt DJ, Bennett PH, Knowler WC: Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes. BMJ. 1994, 308: 1323-1328. 10.1136/bmj.308.6940.1323.

  6. 6.

    Engelgau MM, Thompson TJ, Herman WH, Boyle JP, Aubert RE, Kenny SJ, Badran A, Sous ES, Ali MA: Comparison of fasting and 2-hour glucose and HbA1c levels for diagnosing diabetes. Diagnostic criteria and performance revisited. Diabetes Care. 1997, 20: 785-791. 10.2337/diacare.20.5.785.

  7. 7.

    The Expert Committee on the diagnosis and classification of diabetes mellitus: Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1997, 20: 1183-1197.

  8. 8.

    Pang C, Jia L, Jiang S, Liu W, Hou X, Zuo Y, Gu H, Bao Y, Wu Q, Xiang K, Gao X, Jia W: Determination of diabetic retinopathy prevalence and associated risk factors in Chinese diabetic and pre-diabetic subjects: Shanghai diabetic complications study. Diabetes Metab Res Rev. 2012, 28: 276-283. 10.1002/dmrr.1307.

  9. 9.

    The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993, 329: 977-986.

  10. 10.

    UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998, 352: 837-853.

  11. 11.

    Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, Cuddihy R, Cushman WC, Genuth S, Grimm RH, Hamilton BP, Hoogwerf B, Karl D, Katz L, Krikorian A, O'Connor P, Pop-Busui R, Schubart U, Simmons D, Taylor H, Thomas A, Weiss D, Hramiak I: Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010, 376: 419-430. 10.1016/S0140-6736(10)60576-4.

  12. 12.

    Wong TY, Liew G, Tapp RJ, Schmidt MI, Wang JJ, Mitchell P, Klein R, Klein BE, Zimmet P, Shaw J: Relation between fasting glucose and retinopathy for diagnosis of diabetes: three population-based cross-sectional studies. Lancet. 2008, 371: 736-743. 10.1016/S0140-6736(08)60343-8.

  13. 13.

    Massin P, Lange C, Tichet J, Vol S, Erginay A, Cailleau M, Eschwège E, Balkau B: Hemoglobin A1c and fasting plasma glucose levels as predictors of retinopathy at 10 years: the French DESIR study. Arch Ophthalmol. 2011, 129: 188-195. 10.1001/archophthalmol.2010.353.

  14. 14.

    Miyazaki M, Kubo M, Kiyohara Y, Okubo K, Nakamura H, Fujisawa K, Hata Y, Tokunaga S, Iida M, Nose Y, Ishibashi T: Comparison of diagnostic methods for diabetes mellitus based on prevalence of retinopathy in a Japanese population: the Hisayama Study. Diabetologia. 2004, 47: 1411-1415.

  15. 15.

    Sabanayagam C, Liew G, Tai ES, Shankar A, Lim SC, Subramaniam T, Wong TY: Relationship between glycated haemoglobin and microvascular complications: is there a natural cut-off point for the diagnosis of diabetes?. Diabetologia. 2009, 52: 1279-1289. 10.1007/s00125-009-1360-5.

  16. 16.

    Colagiuri S, Lee CM, Wong TY, Balkau B, Shaw JE, Borch-Johnsen K: Glycemic thresholds for diabetes-specific retinopathy: implications for diagnostic criteria for diabetes. Diabetes Care. 2011, 34: 145-150. 10.2337/dc10-1206.

  17. 17.

    Xin Z, Yuan MX, Li HX, Hua L, Feng JP, Shi J, Zhu XR, Cao X, Yang JK: Evaluation for fasting and 2-hour glucose and HbA1c for diagnosing diabetes based on prevalence of retinopathy in a Chinese population. PLoS One. 2012, 7: e40610-10.1371/journal.pone.0040610.

  18. 18.

    Ito C: Evidence for diabetes mellitus criteria in 2010 using HbA1c. Diabetol Int. 2013, 4: 9-15. 10.1007/s13340-012-0086-7.

  19. 19.

    Selvin E, Francis LM, Ballantyne CM, Hoogeveen RC, Coresh J, Brancati FL, Steffes MW: Nontraditional markers of glycemia: associations with microvascular conditions. Diabetes Care. 2011, 34: 960-967. 10.2337/dc10-1945.

  20. 20.

    Kim WJ, Park CY, Park SE, Rhee EJ, Lee WY, Oh KW, Park SW, Kim SW, Park HS, Kim YJ, Song SJ, Ahn HY: Serum 1,5-anhydroglucitol is associated with diabetic retinopathy in type 2 diabetes. Diabet Med. 2012, 29: 1184-1190. 10.1111/j.1464-5491.2012.03613.x.

  21. 21.

    Tominaga M, Makino H, Yoshino G, Kuwa K, Takei I, Aono Y, Hoshino T, Umemoto M, Shimatsu A, Sanke T, Kuwashima M, Taminato T, Ono J: Report of the committee on standardization of laboratory testing related to diabetes mellitus of the Japan Diabetes Society: determination of reference intervals of hemoglobin A1C (IFCC) and glycoalbumin in the Japanese population. J Japan Diab Soc. 2006, 49: 825-833. (in Japanese)

  22. 22.

    Ma XJ, Pan JM, Bao YQ, Zhou J, Tang JL, Li Q, Xiang KS, Jia WP: Combined assessment of glycated albumin and fasting plasma glucose improves the detection of diabetes in Chinese subjects. Clin Exp Pharmacol Physiol. 2010, 37: 974-979. 10.1111/j.1440-1681.2010.05417.x.

  23. 23.

    Furusyo N, Koga T, Ai M, Otokozawa S, Kohzuma T, Ikezaki H, Schaefer EJ, Hayashi J: Utility of glycated albumin for the diagnosis of diabetes mellitus in a Japanese population study: results from the Kyushu and Okinawa Population Study (KOPS). Diabetologia. 2011, 54: 3028-3036. 10.1007/s00125-011-2310-6.

  24. 24.

    Yamanouchi T, Akanuma Y, Toyota T, Kuzuya T, Kawai T, Kawazu S, Yoshioka S, Kanazawa Y, Ohta M, Baba S, Kosaka K: Comparison of 1,5-anhydroglucitol, HbA1c, and fructosamine for detection of diabetes mellitus. Diabetes. 1991, 40: 52-57. 10.2337/diab.40.1.52.

  25. 25.

    Robertson DA, Alberti KG, Dowse GK, Zimmet P, Tuomilehto J, Gareeboo H: Is serum anhydroglucitol an alternative to the oral glucose tolerance test for diabetes screening?. Diabet Med. 1993, 10: 56-60. 10.1111/j.1464-5491.1993.tb01997.x.

  26. 26.

    Goto M, Yamamoto-Honda R, Shimbo T, Goto A, Terauchi Y, Kanazawa Y, Noda M: Correlation between baseline serum 1,5-anhydroglucitol levels and 2-hour post-challenge glucose levels during oral glucose tolerance tests. Endocr J. 2011, 58: 13-17. 10.1507/endocrj.K10E-224.

  27. 27.

    Koga M, Kasayama S: Clinical impact of glycated albumin as another glycemic control marker. Endocr J. 2010, 57: 751-762. 10.1507/endocrj.K10E-138.

  28. 28.

    Kim WJ, Park CY: 1,5-anhydroglucitol in diabetes mellitus. Endocrine. 2013, 43: 33-40. 10.1007/s12020-012-9760-6.

  29. 29.

    Ito C, Maeda R, Ishida S, Harada H, Inoue N, Sasaki H: Importance of OGTT for diagnosing diabetes mellitus based on prevalence and incidence of retinopathy. Diabetes Res Clin Pract. 2000, 49: 181-186. 10.1016/S0168-8227(00)00156-X.

  30. 30.

    Fukuhara M, Arima H, Ninomiya T, Hata J, Hirakawa Y, Doi Y, Yonemoto K, Mukai N, Nagata M, Ikeda F, Matsumura K, Kitazono T, Kiyohara Y: White-coat and masked hypertension are associated with carotid atherosclerosis in a general population: the Hisayama Study. Stroke. 2013, 44: 1512-1517. 10.1161/STROKEAHA.111.000704.

  31. 31.

    Hata J, Ninomiya T, Hirakawa Y, Nagata M, Mukai N, Gotoh S, Fukuhara M, Ikeda F, Shikata K, Yoshida D, Yonemoto K, Kamouchi M, Kitazono T, Kiyohara Y: Secular trends in cardiovascular disease and its risk factors in Japanese: half century data from the Hisayama Study, 1961-2009. Circulation. 2013, 128: 1198-1205.

  32. 32.

    Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998, 15: 539-553. 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S.

  33. 33.

    Committee on the standardization of diabetes mellitus-related laboratory testing of Japan Diabetes Society: International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values. J Diabetes Invest. 2012, 3: 39-40. 10.1111/j.2040-1124.2012.00207.x.

  34. 34.

    World Health Organization: Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and Mineral Nutrition Information System. 2011, Geneva: World Health Organization

  35. 35.

    Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A: Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009, 53: 982-992. 10.1053/j.ajkd.2008.12.034.

  36. 36.

    National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002, 39: S1-S266.

  37. 37.

    Wilkinson CP, Ferris FL, Klein RE, Lee PP, Agardh CD, Davis M, Dills D, Kampik A, Pararajasegaram R, Verdaguer JT: Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003, 110: 1677-1682. 10.1016/S0161-6420(03)00475-5.

  38. 38.

    DeLong ER, DeLong DM, Clarke-Pearson DL: Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988, 44: 837-845. 10.2307/2531595.

  39. 39.

    Likhari T, Gama R: Glycaemia-independent ethnic differences in HbA1c in subjects with impaired glucose tolerance. Diabet Med. 2009, 26: 1068-1069. 10.1111/j.1464-5491.2009.02803.x.

  40. 40.

    Davidson MB, Schriger DL: Effect of age and race/ethnicity on HbA1c levels in people without known diabetes mellitus: implications for the diagnosis of diabetes. Diabetes Res Clin Pract. 2010, 87: 415-421. 10.1016/j.diabres.2009.12.013.

  41. 41.

    Morita K, Saruwatari J, Miyagawa H, Uchiyashiki Y, Oniki K, Sakata M, Kajiwara A, Yoshida A, Jinnouchi H, Nakagawa K: Association between aldehyde dehydrogenase 2 polymorphisms and the incidence of diabetic retinopathy among Japanese subjects with type 2 diabetes mellitus. Cardiovasc Diabetol. 2013, 12: 132-10.1186/1475-2840-12-132.

  42. 42.

    Waugh NR, Shyangdan D, Taylor-Phillips S, Suri G, Hall B: Screening for type 2 diabetes: a short report for the National Screening Committee. Health Technol Assess. 2013, 17: 1-90.

  43. 43.

    Kramer CK, Araneta MR, Barrett-Connor E: A1C and diabetes diagnosis: the Rancho Bernardo study. Diabetes Care. 2010, 33: 101-103. 10.2337/dc09-1366.

  44. 44.

    Hjellestad ID, Astor MC, Nilsen RM, Søfteland E, Jonung T: HbA1c versus oral glucose tolerance test as a method to diagnose diabetes mellitus in vascular surgery patients. Cardiovasc Diabetol. 2013, 12: 79-10.1186/1475-2840-12-79.

  45. 45.

    Penno G, Solini A, Zoppini G, Orsi E, Fondelli C, Zerbini G, Morano S, Cavalot F, Lamacchia O, Trevisan R, Vedovato M, Pugliese G: Hemoglobin A1c variability as an independent correlate of cardiovascular disease in patients with type 2 diabetes: a cross-sectional analysis of the Renal Insufficiency and Cardiovascular Events (RIACE) Italian multicenter study. Cardiovasc Diabetol. 2013, 12: 98-10.1186/1475-2840-12-98.

  46. 46.

    Ikeda F, Doi Y, Ninomiya T, Hirakawa Y, Mukai N, Hata J, Shikata K, Yoshida D, Matsumoto T, Kitazono T, Kiyohara Y: Haemoglobin A1c even within non-diabetic level is a predictor of cardiovascular disease in a general Japanese population: the Hisayama study. Cardiovasc Diabetol. 2013, 12: 164-10.1186/1475-2840-12-164.

  47. 47.

    Doi Y, Kubo M, Yonemoto K, Ninomiya T, Iwase M, Arima H, Hata J, Tanizaki Y, Iida M, Kiyohara Y: Fasting plasma glucose cutoff for diagnosis of diabetes in a Japanese population. J Clin Endocrinol Metab. 2008, 93: 3425-3429. 10.1210/jc.2007-2819.

  48. 48.

    Madsen-Bouterse SA, Kowluru RA: Oxidative stress and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Rev Endocr Metab Disord. 2008, 9: 315-327. 10.1007/s11154-008-9090-4.

  49. 49.

    Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C: Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006, 295: 1681-1687. 10.1001/jama.295.14.1681.

  50. 50.

    Ceriello A, Esposito K, Piconi L, Ihnat MA, Thorpe JE, Testa R, Boemi M, Giugliano D: Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes. 2008, 57: 1349-1354. 10.2337/db08-0063.

  51. 51.

    Shiraiwa T, Kaneto H, Miyatsuka T, Kato K, Yamamoto K, Kawashima A, Kanda T, Suzuki M, Imano E, Matsuhisa M, Hori M, Yamasaki Y: Postprandial hyperglycemia is a better predictor of the progression of diabetic retinopathy than HbA1c in Japanese type 2 diabetic patients. Diabetes Care. 2005, 28: 2806-2807. 10.2337/diacare.28.11.2806.

  52. 52.

    Kilpatrick ES, Keevilt BG, Richmond KL, Newland P, Addison GM: Plasma 1,5-anhydroglucitol concentrations are influenced by variations in the renal threshold for glucose. Diabet Med. 1999, 16: 496-499. 10.1046/j.1464-5491.1999.00093.x.

  53. 53.

    Nowatzke W, Sarno MJ, Birch NC, Stickle DF, Eden T, Cole TG: Evaluation of an assay for serum 1,5-anhydroglucitol (GlycoMark™) and determination of reference intervals on the Hitachi 917 analyzer. Clin Chim Acta. 2004, 350: 201-209. 10.1016/j.cccn.2004.08.013.

  54. 54.

    Nathan DM, Steffes MW, Sun W, Rynders GP, Lachin JM: Determining stability of stored samples retrospectively: the validation of glycated albumin. Clin Chem. 2011, 57: 286-290. 10.1373/clinchem.2010.150250.

  55. 55.

    Harano T: Hemoglobinopathy in Japan: detection and analysis. Rinsho Byori. 1999, 47: 215-223. (in Japanese)

Download references


The authors thank the staff of the Division of Health and Welfare of Hisayama for their cooperation in this study.

This study was supported in part by Grants-in-Aid for Scientific Research on Innovative Areas (22116010) and for Scientific Research (A) (25253048 and 22240073), (B) (25293428), and (C) (23590797, 23590798, 23500842, 24590796, 24590797, and 25460758) from the Ministry of Education, Culture, Sports, Science and Technology of Japan, by Health and Labour Sciences Research Grants of the Ministry of Health, Labour and Welfare of Japan (Comprehensive Research on Life-Style Related Diseases including Cardiovascular Diseases and Diabetes Mellitus: H22-Junkankitou [Seishuu]-Ippan-005, H23-Junkankitou [Seishuu]-Ippan-005, H25-Junkankitou [Seishuu]-Ippan-005, H25-Junkankitou [Seishuu]-Ippan-009, and H25-Junkankitou [Seishuu]-Sitei-022; and Comprehensive Research on Dementia: H25-Ninchisho-Ippan-004), and by a research grant from the Japan Diabetes Society.

Author information

Correspondence to Naoko Mukai.

Additional information

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

NM contributed to the study concept and design, data collection, data analysis, data interpretation, and drafting of the manuscript. MY contributed to the data collection, data interpretation, and drafting of the manuscript. TN, JH, YH, FI, and MF contributed to the data collection and data interpretation. TH and DK measured the samples and contributed to the data interpretation. MK, UN, and TK contributed to the data interpretation and the critical revision of the manuscript for important intellectual content. YK contributed to the data collection, data interpretation, drafting of the manuscript, obtained funding, and study supervision. All authors provided critical review of the draft and approved the final version.

Authors’ original submitted files for images

Below are the links to the authors’ original submitted files for images.

Authors’ original file for figure 1

Authors’ original file for figure 2

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Cite this article

Mukai, N., Yasuda, M., Ninomiya, T. et al. Thresholds of various glycemic measures for diagnosing diabetes based on prevalence of retinopathy in community-dwelling Japanese subjects: the Hisayama Study. Cardiovasc Diabetol 13, 45 (2014).

Download citation


  • Diagnostic criteria
  • Hemoglobin A1c
  • Glycated albumin
  • 1,5-anhydroglucitol
  • Fasting plasma glucose
  • 2-hour postload glucose
  • Retinopathy